- Work address
-
Albert Baertsoenkaai 3
9000 Gent - Sandra.VanLint@UGent.be
Show
Sort by
-
Towards the use of interleukin-1β as vaccine adjuvant
-
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice
-
IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination
-
Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses
-
- Journal Article
- A1
- open access
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
-
Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments
-
IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination
-
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
-
Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses
-
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells